$1.610
0.000 (0.00%)收盤時
BMRA 資訊
BMRA 事件
Biomerica Files $250M Mixed Securities Shelf
Biomerica files $250M mixed securities shelf
Selling Stockholders Plan to Sell 1.4M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.4M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Biomerica Completes Private Placement of 1,393,705 Shares, Raising Approximately $2.23M
Biomerica announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the company's common stock at a price of $1.60 per share, expected to provide approximately $2.23M in gross proceeds to the company. The financing was priced at $1.60 at the time the definitive agreements were entered into and includes no warrants or discounted securities. Participation in the financing included B. Riley Principal Capital , certain executives and employees of B. Riley Securities, the company's Chief Executive Officer, and all members of the company's Board of Directors, reflecting meaningful alignment between outside investors and company leadership. Following the closing of the financing, the company expects to have approximately 4,588,968 shares of the company's common stock outstanding on a pro forma basis, with the shares issued in the financing representing approximately 30.4% of pro forma shares outstanding. The company intends to use the proceeds to strengthen its balance sheet and fund operations as its Board of Directors continues to evaluate a range of potential strategic opportunities intended to maximize shareholder value.
Biomerica Engages B. Riley as Financial Advisor
Biomerica announced that it has engaged B. Riley as its exclusive financial advisor in connection with the evaluation and potential pursuit of potential strategic opportunities. Under the engagement, B. Riley may assist the company in reviewing, evaluating and negotiating potential acquisitions, mergers, joint ventures, partnerships, spin-offs and other strategic combinations.
Biomerica Enters Service Agreement with Life Sciences Company, Contract Exceeds $1.75M
Biomerica announced it has entered into a master services agreement with a confidential life sciences company to develop proprietary in vitro diagnostic assays. The engagement carries an initial contract development target fee of over $1.75M, to be earned across multiple statements of work under the MSA. Biomerica was chosen following a competitive evaluation in which multiple CDMO organizations were assessed. The MSA establishes an initial three-year term with automatic one-year renewals. All development work will be performed at Biomerica's FDA-licensed, ISO 13485-certified facility in Irvine, California. Revenue will be recognized on a milestone-completion basis as individual SOW deliverables are accepted.
相關文章
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。





